Diphereline PR Indications/Uses

Prostate cancer: Treatment of locally advanced prostate cancer when used alone or as concomitant and adjuvant to radiotherapy.
Treatment of metastatic prostate cancer.
Patients who have not previously received hormone therapy show a more marked response to the treatment and response more frequently if the patient has not previously received another hormone treatment.
Genital and Extragenital Endometriosis (Stage I to Stage IV): Treatment should not be administered for more than 6 months (see Adverse Reactions). It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.
Central precocious puberty (before 8 years in girls and 10 years in boys).
3.75 mg: Treatment of uterine fibromyomas prior to surgery: Associated with anaemia (haemoglobin less than or equal to 8 g/dl). When a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery.
The treatment duration is restricted to 3 months.
Breast cancer: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy (see Contraindications, Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).